Chugai Pharmaceutical announced that it will newly establish, Translational Clinical Research (TCR) division as of April 1, 2015. The division specialises in early clinical development and work to solidify its functions in order to aim at rapidly acquiring Proof-of-Concept (PoC) for projects under development that had been discovered and created in-house, and speedy shift to global development.

Chugai’s mid-term management plan “ACCEL 15”, sets “Acceleration of global development” as one of the top priority challenges. Newly establishing the TCR Div. as one of the measures to address those challenges will enable to build a development setup equipped with top-level quality and speed in the world, which would allow Chugai to obtain PoC at an early stage. Speedy acquisition of PoC is essential to submit an application at the earliest time and launch globally competitive products created in-house, which will contribute to the patients, and ultimately lead to maximising product value.